SecBot SecBot
8-K ·Filed Aug 13, 2026

PYXS

Pyxis Oncology, Inc.
MIXED
Impact 5/10
Horizonmonths Processed3mo ago SEC0001193125-26-347911
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The wider net loss and elevated G&A costs are near-term negatives, but the $50M financing removes near-term cash runway risk through Q2 2027. The stock will likely trade on the upcoming MICVO data readouts in Fall 2026 and Q4 2026, which are the primary catalysts. Monitor for any pre-data announcements or changes to the clinical timeline.

DirectionMixed
Confidencehigh
Horizonmonths

PYX-201

◆ Mixed Named in this 8-K
Impact
Phase
Phase 1 / Phase 1/2
Time to market
At least 2-3 years, assuming Phase 3 trial (planned mid-2027) succeeds and leads to an NDA filing. No regulatory filing has occurred yet.
Next catalyst
None dated

What to watchThe next near-term catalyst is the EORTC-NCI-AACR late-breaking oral presentation (Nov 18-20, 2026), though the top-line data has already been disclosed. The true binary events are: Q4 2026 updated combo data, Q1 2027 End-of-Phase 2 meeting with FDA, and H1 2027 overall survival data from the monotherapy study, any of which could drive major moves. The $3.50 common warrant exercise trigger (requiring both shareholder approval and OS data) creates an additional overhang that could cap upside until clarity emerges.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.01
T+0 close · Aug 13, 2026 · via day close
Latest settled
−44.85%
T+60 · $1.66
Vs SPY
−39.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $3.01entry
  2. T+1 · 3mo ago 0.00%α +0.20% · $3.01
  3. T+5 · 3mo ago +3.65%α +5.62% · $3.12
  4. T+20 · 2mo ago +6.64%α +8.39% · $3.21
  5. T+60 · 11d ago −44.85%α −39.38% · $1.66

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pyxis Oncology reported Q2 2026 results with a net loss of $25.3M ($0.40/share), wider than the prior year's $18.4M loss, driven by higher G&A costs. The company completed a ~$50M private placement, extending its cash runway into Q2 2027, and reiterated key MICVO data readouts in Fall 2026 and Q4 2026. The wider loss and lack of revenue are negatives, but the strengthened balance sheet and on-track pipeline milestones provide a counterbalance for a pre-revenue clinical-stage biotech.

Key Financial Metrics

EPS
−$0.40
est −$0.34 · -17.6%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Net loss of $25.3M ($0.40/share) for Q2 2026 vs $18.4M ($0.30/share) in Q2 2025.
  • Completed private placement with upfront gross proceeds of ~$50M, extending cash runway into Q2 2027.
  • Cash and investments were $34.5M as of June 30, 2026, plus $10M received on June 30 from the private placement.
  • MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC on track for Fall 2026; combination data with pembrolizumab on track for Q4 2026.
  • R&D expenses decreased to $16.1M from $17.1M YoY; G&A expenses increased to $9.9M from $5.4M YoY due to severance and stock-based compensation.

Financial Impact

Net loss widened by $6.9M YoY to $25.3M; cash runway extended into Q2 2027 via $50M private placement.

net losscash runwaydilution

Risk Factors

  • Dilution from the private placement and potential warrant exercises.
  • Clinical trial risk, MICVO data may not meet efficacy or safety expectations.
  • Cash runway only extends to Q2 2027, requiring additional financing before data maturity.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-347911
Document: pyxs-20260813.htm0001193125-26-347911
Document: 0001193125-26-347911-index-headers.html0001193125-26-347911
Document: 0001193125-26-347911-index.html0001193125-26-347911
Document: 0001193125-26-347911.txt0001193125-26-347911
8-K Data (Synthetic)0001193125-26-347911

Track record

25 reports on PYXS

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
  3. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
  5. Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
  6. Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
  7. Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
  8. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
  9. Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
  10. Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026